Grace Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed Jun 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jun 18, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
(a) On June 17, 2026, following continued evaluation of strategic priorities and focus on GTx-104, our Board of Directors determined that we will not resume internal development funding for GTx-102 or GTx-101 under our current operating plan. Accordingly, we determined that the remaining carrying values of the GTx-102 IPR&D asset and the GTx-101 IPR&D asset are no longer recoverable on an internal-development basis.
As of March 31, 2026, the remaining capitalized carrying value of GTx-102 IPR&D was $9.2 million and the remaining capitalized carrying value of GTx-101 IPR&D was $4.3 million. We expect to recognize an impairment charge for the full remaining carrying values of the GTx-102 IPR&D asset and the GTx-101 IPR&D asset in the first quarter of fiscal year 2027. The Company does not expect the impairment charges to result in future cash expenditures.
(b) During the fiscal quarter ended March 31, 2026, none of our directors or officers adopted orterminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.